Menu
Search
|

Menu

Close
X

Solid Biosciences Inc SLDB.OQ (NASDAQ Stock Exchange Global Select Market)

10.14 USD
+0.00 (+0.00%)
As of Sep 13
Previous Close 10.14
Open 10.22
Volume 59,877
3m Avg Volume 160,863
Today’s High 10.44
Today’s Low 9.99
52 Week High 54.05
52 Week Low 4.32
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-1.612
FY18
-2.138
FY17
-1.220
FY16
-0.195
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Andrey Zarur
Chairman of the Board, Co-Founder, Since
Salary: --
Bonus: --
Ilan Ganot
President, Chief Executive Officer, Co-Founder, Director, Since 2019
Salary: $450,000.00
Bonus: $247,500.00
Jennifer Ziolkowski
Chief Financial Officer, Treasurer, Since 2019
Salary: $176,060.00
Bonus: $124,700.00
Alvaro Amorrortu
Chief Operating Officer, Since 2017
Salary: $330,000.00
Bonus: $132,000.00
Joel Schneider
Chief Technology Officer and Head of Exploratory Research and Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

141 Portland St Fl 5
CAMBRIDGE   MA   02139-1937

Phone: +1617.3374680

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

SPONSORED STORIES